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Abstract 
 Prostate cancer is the most frequently diagnosed cancer among men, with an incidence 
rate of 1 in 7. The mechanisms regulating its abnormal growth and metastasis are not fully 
understood. Transforming Growth Factor-Beta (TGF-β) has been described as both a negative 
prognostic indicator and a growth promoter in prostate cancer. The p21-Activated kinase 2 
(Pak2) enzyme regulates growth and migration of normal cells and has been shown to be 
activated by TGF-β.  My hypothesis proposes that Pak2 regulates the aberrant migratory 
properties of prostate cancer. Multiple prostate cancer cell lines, representing multiple stages in 
disease development were used to define protein and gene expression levels within the Pak2 
signaling cascade. P-Merlin levels were used to determine Pak2 activity. There is a shift in the 
ratio of Pak2 stimulatory proteins with a dominance of CDC42 corresponding with disease 
progression. The ratio of Merlin to Erbin is altered in all prostate cancer cells. There is an 
increase in P-Merlin levels corresponding to progression of the disease, indicating an increase in 
basal Pak2 activity. Pak2 inhibition blocked TGF-β promoted migration in highly metastatic 
prostate cancer cells PC-3 and DU145. These results demonstrate the Pak2 signaling pathway is 
not only aberrantly active but that regulates TGF-β induced migration in prostate cancer. 
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Chapter I - Introduction 
1.1 Prostate Cancer Statistics 
Prostate cancer is the second most common cancer affecting men worldwide, especially 
in western developed countries. The incidence of prostate cancer diagnosis varies around the 
world, Caribbean men have a 26% risk of being diagnosed by the age of 74 years old, while in 
Asia the risk is 0.15%, indicating that ethnicity may play a role in prostate cancer incidence 
(Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2015). Prostate cancer 
mortality falls to second place only to lung cancer deaths worldwide. According to the Canadian 
Cancer Society, one in seven Canadian men are expected to be diagnosed with prostate cancer in 
their life time. Approximately 24,000 new cases are expected per year in Canada, representing 
24% of all new male cancer cases. In the United States, prostate cancer has become the second 
leading cancer in males (in new cases and deaths) representing 27% of all new cancer cases. 
Prostate cancer is more commonly diagnosed in males between 60 to 69 years old. As men get 
older the risk of developing prostate cancer increases (Canadian Cancer Society’s Advisory 
Committee on Cancer Statistics, 2015; Hodson, 2015; Siegel et al., 2014). 
Prostate cancer accounts for the majority of bone metastases diagnosed in men in the 
USA. Studies utilizing large databases found that 7.7 % of men with prostate cancer had 
evidence of bone metastasis at diagnosis. These men were more likely to be older than a matched 
cohort of men without bone metastasis with a median age of 76 versus 74 (Brawley, 2012). Race 
and comorbidity do not appear to influence the risk of presenting bone metastasis at diagnosis. 
The risk of death is 6.6 fold higher for those with bone metastasis and no evidence of skeletal-
related events at presentation compared to those without bone metastases (Sathiakumar et al., 
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2011). When both bone metastasis and skeletal-related events are present at diagnosis, the death 
risk increases to 10.2 fold (Bubendorf et al., 2000). 
1.2 The Prostate Gland 
The prostate is an exocrine gland considered to be slightly bigger than a walnut, about 3 
centimeters in length weighting approximately 20 grams. It is located underneath the bladder, 
surrounding the urethra. The gland’s principal function is to produce, store and secrete seminal 
fluid components (Huggins et al., 1942).  The prostate was first described as a gland composed 
of 3 zones by McNeal (Figure 1.1); the transitional zone, the central zone and the peripheral 
zone (the largest zone), the origin of 70 to 80% of prostate carcinomas (McNeal, 1969; Myers, 
2000). 
                           
Figure 1. 1 – Anatomy of a normal human prostate gland. Used with permission Cold Spring Harbor 
Laboratory Press, Abate-Shen (2000) 
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There are three main epithelial cell types identified in the normal prostate: the basal, 
luminal, and neuroendocrine cells (Figure 1.2). The neuroendocrine cells do not express 
androgen receptor, making them androgen independent cells. Their exact role and function is 
unclear, but it is established that they have a role in the growth and differentiation of the prostate 
and therefore, implicated in carcinogenesis. Neuroendocrine cells are characterized by the 
expression of chromogranin A, serotonin, synaptophysin and neuro specific enolase (NSE). The 
basal layer is considered to be the proliferative compartment of the prostate and its cells express 
p63, cytokeratins 5 and 14, and the cell surface marker CD44. The luminal layer consists of 
androgen dependent cells. The androgen receptor is present in luminal cells which also express 
the cytokeratins 8 and 18, and the cell surface marker CD57 (Abate-Shen and Shen, 2000; Long 
et al., 2005; Vashchenko N and Abrahamsson PA, 2005). Additionally, the luminal cells are the 
source of kallikrein 3, also known as the prostate specific antigen (PSA; Lilja et al., 1987). 
                    
Figure 1. 2 - The three differentiated cell types in the prostate epithelium. Used with permission Cold 
Spring Harbor Laboratory Press Abate-Shen (2000) 
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1.3 Initiation and Progression of Prostate Cancer  
Through the development of prostate cancer studies, scientists believe that prostatic 
intraepithelial neoplasia (PIN), are the precursor of prostate cancer. Reports suggest a transition 
exists between atrophic epithelium and adenocarcinoma in which areas with chronic 
inflammation and a high grade PIN present signs of oxidative stress, genetic instability and a 
cluster of inflammation (Marzo et al., 2007; Weir, 2015). There are two different types of PIN, 
low grade and high grade, however, the term PIN is commonly applied to indicate the high-grade 
form. PIN is typically characterised by a drastic reduction in the basal cell population, and 
exponential increase in luminal cells. These luminal cells develop alterations in their structure 
resulting in the loss of adhesion and changes in their cytoskeleton. PIN progression into 
adenocarcinoma is attributed to the inactivation of tumor suppressors and the activation of 
oncogenes. Adenocarcinoma is generally recognized by the absence of basal cells and extensive 
proliferation of altered luminal cells. These luminal cells have changed their structure, motility, 
proliferation and gained invasive properties that permit them to metastasize throughout the body 
(Abate-Shen and Shen, 2000; Bostwick, 2000; Figure 1.3). In a process referred to as epithelial 
to mesenchymal transition (EMT), epithelial cells lose their cell polarity and cell-cell adhesion, 
gaining migratory and invasive properties similar to mesenchymal cells.  
         
Figure 1. 3 - Progression of prostate cancer. Used with permission Cold Spring Harbor Laboratory 
Press Abate-Shen (2000) 
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Epithelial to mesenchymal transition (EMT) is commonly associated with cancer 
migration, invasion and metastasis. EMT is normally a highly conserved embryonic program 
where polarized immobile epithelial cells transition to motile, mesenchymal-like cells 
(Greenburg and Hay, 1982). During development, this process is reversible in morphology 
ending with a process called mesenchymal to epithelial transition or MET. In contrast, cancer 
cells having already acquired EMT, subsequently undergoing MET leads to acquiring a more 
aggressive phenotype rather than a less aggressive one (Yates et al., 2007).  
The canonical mediators of EMT during embryogenesis are members of the TGF-β 
superfamily and the WNT family (Yang and Weinberg, 2008). The common characteristic of 
EMT is the loss of E-cadherin, associated with decreased cell-cell adhesion, and an increase in 
Vimentin, a major cytoskeletal component of mesenchymal cells. In cancer, EMT is thought to 
allow benign tumors to infiltrate surrounding tissues and metastasize (Xu et al., 2006).   
Due to the EMT molecular alterations, prostate cancer cells become detached at the 
invasive tumor front, migrating out of the tumor cell clusters and traveling through the lymph-
vascular system to metastasize typically to the bone (Vleminckx et al., 1991). The prostate 
cancer metastatic tumor cells interact with growth factors that are produced in or released from 
the bone microenvironment, which plays a crucial role in stimulating bone colonization (Buijs 
and van der Pluijm, 2009; Buijs et al., 2007). Bone metastases occur in more than 90% of 
patients with advanced prostate cancer and a high burden of metastatic disease is associated with 
poor survival (Carlin and Andriole, 2000). In the bone microenvironment, prostate cancer 
metastatic cells acquire osteoblastic properties through independent activation of the Notch 
signaling pathway promoting angiogenesis. (Zayzafoon et al., 2004). Additionally, growth 
factors and alterations in signalling pathways such as TGF-β, epidermal growth factor (EGF), 
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hepatocyte growth factor (HGF), fibroblast growth factor (FGF), and hypoxia, Snail, and Slug 
play prominent roles in EMT induction of the primary tumor and have been identified as 
important stimulators of skeletal metastasis formation (Papachristou and Basdra, 2012).   
1.4 Prostate Cancer Diagnosis  
Prostate cancer mortality rates have been decreasing since early 2000, this can be 
attributed to improved treatments and the introduction of the frequency of prostate-specific 
antigen (PSA) testing for its detection (Siegel et al., 2014; Siegel et al., 2015). PSA expression 
has been commonly applied as the main tool for prostate cancer detection; it screens for high 
levels of PSA in the blood enabling early detection of prostate cancer. However, an elevated 
reading is not necessarily due to a malignant tumor, mistakenly labelling many men who do not 
have cancer. The US National Cancer Institute estimates that for every 1,000 men screened 
regularly with the PSA test over the course of a decade, as many as 120 will get a false-positive 
result, while 110 will get an appropriate positive diagnosis (Sohn, 2015).  
Metastatic prostate cancer is commonly fatal and unfortunately existing therapies do not 
substantially increase survival. Over 80% of patients show a positive response to androgen 
deprivation therapy. However, patients with metastatic prostate cancer eventually experience 
disease progression after androgen deprivation therapy. The principal reason for the inability of 
the androgen deprivation therapy to successfully increase survival in men with metastatic 
prostatic cancer is that the cancer within each individual patients can be heterogeneously 
composed of both androgen dependent and independent prostate cancer cells in these particular 
patients. This heterogeneous state is present even before the therapy is initiated, making the 
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therapy ineffective on the pre-existing androgen independent cells (Heinlein and Chang, 2004; 
Kyprianou et al., 1990). 
While early detection of prostate cancer is important for diagnosis and prognosis, the 
main concern is distinguishing between the aggressive and the indolent forms of the disease. 
Once the cancer starts to spread to the nearby lymph nodes, bone or visceral organs; the 5 year 
estimated survival rate drops to 28% (Deweerdt, 2015; Stattin et al., 2015). For the indolent form 
active surveillance is selected when physicians consider men to have a low risk of disease 
progression after results from the diagnosis with their Gleason score, clinical stage of the cancer 
progression and their PSA levels (Wadman, 2015). 
1.5 Transforming Growth Factor β 
Transforming Growth Factor β (TGF-β) is the prototypic member of a family of 
cytokines that control numerous cellular functions including cell migration, proliferation, 
differentiation, apoptosis and EMT (Grant and Kyprianou, 2013; Massagué, 2008). TGF-β’s 
(TGF-β1, TGF-β2, and TGF-β3) stimulate the cellular response through the TGF-β type I 
(TGFβRI) and type II (TGFβRII) receptor signalling complex. Binding of TGF-β to the receptor 
complex induces signal transduction resulting in the activation and phosphorylation of 
transcription factors known as smad2 and smad3 (Franzén et al., 1993; Lin et al., 1992). 
Activation of smad2 and smad3 results in their interaction with a common mediator smad4 
forming an oligomeric complex. This complex is translocated to the nucleus, where it interacts 
with myriad transcriptional co-regulators and other factors that help in the regulation of target 
gene expression elicited by TGF-β (Macías-Silva et al., 1996; Zhang et al., 1996). Both epithelial 
and mesenchymal cells possess this canonical signaling cascade. However, epithelial cells are 
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growth inhibited, while mesenchymal cells are growth stimulated by TGF-β, suggesting a 
difference in the signaling mechanism between cell types. 
In normal epithelial cells, TGF-β stops the cell cycle at the G1 stage stopping 
proliferation, induce differentiation, or promote apoptosis. However, deregulation of TGF-β 
pathway can lead to various pathological conditions, including cancer. When an epithelial cell is 
transformed into a cancer cell, components of the TGF-β signalling pathway may be mutated 
(Pasche, 2001), making it impossible for TGF-β to negatively control cell growth, leading to its 
proliferation. The surrounding stromal (mesenchymal) cells proliferate, increasing their 
production of TGF-β. TGF-β acts on the surrounding stromal cells, immune cells, endothelial 
and smooth-muscle to cells; stimulating angiogenesis and making the cancer cells more invasive 
(Heldin et al., 2009; Principe et al., 2014). 
TGF-β has a complex role in cancer. Initially, it was identified as a tumor suppressor 
since it inhibits the growth of cells and induces apoptosis (Nguyen and Pollard, 2000). However, 
at later stages of tumor progression TGF-β acts as a tumor promoter (Xie et al., 2002). At a later 
stage of the disease, the tumor cells lose their ability to be growth arrested by TGF-β, but retain 
their ability to undergo EMT, which correlates to increased invasiveness and metastasis 
(Kingsley et al., 2007). In addition, the suppression of the immune system and stimulation of 
angiogenesis by TGF-β also contributes to its tumor promoting effects (Massagué, 2008; 
Moustakas and Heldin, 2007). 
Smad pathways are part of the canonical TGF-β signaling pathway, though examples of 
non-smad pathways activated by TGF-β also exist. These non-smad pathways include the 
extracellular signal regulated kinase (ERK) pathway (Blanchette et al., 2001; Hough et al., 
2012), the c-Jun N-terminal kinases (JNK) pathway (Wang et al., 1997), the Phosphatidylinositol 
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3-kinases (PI3K) pathway (Wilkes et al., 2005) and the p21 activated kinases 2 (Pak2) pathway 
(Wilkes et al., 2003), among other pathways (Moustakas and Heldin, 2005).  
1.5.1 TGF-β and the PI3K Pathway 
Phosphatidylinositol 3 kinase (PI3K) is a family of proteins that phosphorylate the 3'-
hydroxyl group on the inositol ring of phosphoinositides on the inner side of the plasma 
membrane (Vanhaesebroeck and Waterfield, 1999). The PI3K family is divided into three 
different classes: Class I, Class II, and Class III. The class I are heterodimeric molecules 
commonly composed of a p85 regulatory and p110 catalytic subunit, primarily responsible for 
mediating the transduction of signals from growth factors and receptors. There is an exception to 
this rule in that the p110γ catalytic subunit associates with a p101regulatory subunit as part of 
the G-Coupled protein signaling cascade. The Class II and III PI3K are different from the Class I 
in structure and function. A distinct feature of Class II PI3Ks is the C-terminal C2 domain 
(Leevers et al., 1999). Class I PI3K (referred to as PI3K) is involved in the generation of various 
lipid effectors resulting in promotion of the phosphorylation of several protein substrates whose 
activity has been linked to cell growth, cellular differentiation, motility, survival, adhesion, and 
cytoskeletal organization (Jeong and Kim, 2004; Katso et al., 2001). In TGF-β induced EMT, in 
particular, PI3K has been shown to activate Snail and Slug through Ras-MAPK. Slug triggers the 
steps of desmosomal disruption, cell spreading, and partial separation at cell–cell borders, which 
comprise the first and necessary phase of the EMT process (Savagner et al., 1997). 
TGF-β receptors I and II activate the PI3K pathway promoting cell survival and enabling 
protection from TGF-β -induced apoptosis in kidney visceral epithelial cells (Schiffer et al., 
2004). Migratory metastatic breast cancer cells produce large amounts of TGF-β, which in turn 
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stimulates the PI3K pathway, activating the protein kinase B, also known as AKT, and ERK 
pathway to enhance their motility (Ueda et al., 2004). In a similar process, mammary epithelial 
cells transformed by the overexpression of the epithelial growth factor receptor 2 (HER2) 
display enhanced motility generated by the activation of Rac1 through TGF-β. These examples 
represent the ability for TGF- β to use smad and non-smad signals to generate morphological 
responses in the cell (Dumont et al., 2003; Ueda et al., 2004).  
1.6 Pak2 
The P21 activated kinase (Pak) family are a major downstream effector of the small 
GTPase Rac1 and cell division control protein 42 (CDC42), which are involved in actin-based 
cytoskeletal remodeling. The Pak family binds to CDC42 and Rac1 through a GTPase binding 
domain also known as a CDC42/Rac interactive binding domain (Renkema and Pulkkinen, 
2002). There are six human known isoforms of Pak, and they are classified into two subgroups: 
Group A, includes Pak 1 to 3, and Group B, Pak 4 to 6. Group A has an N-terminal regulatory 
domain and a carboxyl terminal kinase domain. Group B also has an N-terminal domain and a 
carboxyl terminal kinase domain, but their GTPase binding domain retains only a 50% similarity 
with those of the group A, suggesting that group A is the primary target of Rac1/CDC42 
activation (Bokoch, 2003; Rane and Minden, 2014).  
Studies have shown the ability of TGF-β to promote the activation of the smad 
independent pathway through specific activation of Pak2. TGF-β activation of Pak2 is a normal 
process that occurs in mesenchymal cells, but it is not a normal event in epithelial cells. Pak2 
activation is necessary for the morphological alterations and proliferative responses induced in 
mesenchymal cells (Hough et al., 2012; Wilkes et al., 2003). Pak2 has been shown to have both 
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anti-apoptotic and pro-apoptotic functions making it unique among the Pak isoforms. Pak 2 pro-
apoptotic functions are attributed to its ability to phosphorylate caspase 7 (Li et al., 2011) 
However, Pak2 is cleaved by caspase 3 at late stages of apoptosis. The Pak2 proteolytic fragment 
mediates phosphorylation of MAPK-interacting serine/threonine protein kinase 1 (MKNK1) 
promoting apoptosis  (Orton et al., 2004) . Group A Paks are the central regulators of CDC42 
and Rac GTPase signalling, and are involved in cytoskeletal rearrangements (Van den Broeke et 
al., 2009).  
 1.6.1 Pak2 Stimulators Rac1 and CDC42 
Rac1, CDC42 and Pak proteins are important for physiological responses to growth 
factors in normal epithelial cells (Somanath and Byzova, 2009) and are involved in the 
promotion of invasion and migration in prostate cancer and ovarian cancer cells by regulating 
microtubule dynamics, adhesion (Goc et al., 2012; Siu et al., 2010).  
Rac1 and CDC42 are part of the Rho family of small GTP-binding proteins with a 
distinct function in actin cytoskeleton organization and regulation of cell motility, including cell 
adhesion, and cell cycle progression (Takai et al., 2001). For instance, Rac1 specifically induces 
membrane ruffling and lamellipodia formation (Nobes and Hall, 1995; Ridley et al., 1992), while 
CDC42 mediates the formation of filopodia and actin micro-spikes, both necessary for 
directional movement of cells, CDC42 has also been reported to regulate the alignment of 
chromosomes during prometaphase and metaphase (Kozma et al., 1995; Yasuda et al., 2004). 
Regarding the importance of these Rho GTPases in tumor cell migration and invasion, it 
has been reported that the p53 tumor suppressor regulates cell migration by inhibiting Rac1 
GTPase activity. Other tumor suppressors had been found to regulate cell motility by 
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suppressing Rac1 and PI3K activities. Rac1appears to be of importance to the migratory 
phenotypes observed in cells with PTEN deficiency and is consider to be involved in the 
signaling of mammalian cells migration (Guo et al., 2003). 
Pak2 activation results from the interactions of the small GTPases Rac1 and CDC42 with 
the PDB domain at the N-terminal regulatory domain of an inactive form of Pak2, resulting in a 
phosphorylation/activation of Pak2 at Serine 20. Conversely, Pak2 inhibition has been reported 
to be the result of the interaction and formation of Erbin and Merlin complexes binding and 
displacing the GTP-bound Rac1-CDC42-Pak2 complex in epithelia (Wilkes et al., 2009; Figure 
1.4). Merlin/Erbin/Pak2 complex formation appears to be cell type dependant in that high levels 
of Merlin in epithelial cells are able to form the complex with increased expression of Erbin, 
inhibiting Pak2 activation. this is important since in fibroblasts Pak2 activation provides growth 
stimulatory signals (Rangwala et al., 2005; Wilkes et al., 2009). 
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Figure 1. 4 - Pak2 activation and inhibition. 
Rac1 and CDC42 interaction results in Pak2 activation (left panel). Merlin and Erbin heterodimer 
disrupt Pak2 interaction with Rac1 and CDC42 inhibiting its activation. 
 1.6.2 Pak2 Inhibitor Erbin 
The LAP [leucine-rich repeat and PDZ domain (PSD-95; Dlg1; ZO-1)] family member 
protein Erbb2 interacting protein (Erbin) was originally reported to be a binding partner for 
ErbB2 subunit of the EGF receptor and was proposed to act as a mediator of basolateral 
trafficking (Borg et al., 2000). Since then, Erbin was characterized for its regulatory roles. Some 
examples include: Erbin interacts with the p120-catenin family members, Erbin has also been 
reported to help suppress the MAPK signaling pathway by binding to Sur-8 and disrupting the 
Sur-8-Ras-Raf complex (Rangwala et al., 2005), Erbin binds to Smads blocking their 
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oligomerization and decreasing their transcriptional output, regardless of phosphorylation status 
(Dai et al., 2007; Warner et al., 2003). 
Erbin is ubiquitously expressed and implicated in regulating many aspects of biological 
behaviors of cancer cells such as cellular proliferation, apoptosis and inflammatory responses 
(Borg et al., 2000). There are reports demonstrating that levels of Erbin are significantly 
decreased or lost in cervical cancer tissues. However there has been no description of Erbin 
levels in prostate cancer. This loss of Erbin has been reported to provide cervical cancer with 
resistance to anoikis by inhibiting STAT3 signaling  (Hu et al., 2013). It has also been reported 
that Erbin plays a positive role in ErbB2-dependent (HER2) breast tumor growth (Tao et al., 
2014). The exact role that Erbin plays during tumorigenesis or the mechanism by which it is 
regulated is not well understood. 
 1.6.3 Pak2 Inhibitor Merlin 
The ubiquitously expressed tumor suppressor Merlin, also known as Neurofibromatosis 
type 2 (NF2) or schwannomin, is part of the ERM (ezrin, radixin, and moesin) family of proteins 
with the function of connecting the actin cytoskeleton to various membrane-associated proteins 
(Golovnina et al., 2005). Merlin has been reported to interact with a number of protein partners 
in order to inhibit many signaling pathways. Overexpression, absence or mutations of this gene 
results in the generation of tumors, including schwannomas, meningiomas, and ependymomas 
(Bretscher et al., 2002). Interestingly, Merlin is localized to adherent junctions and physically 
interacts with its components, suggesting that Merlin helps control the assembly of adherent 
junctions and contact-dependent growth inhibition in sites of cell-cell contact. These results 
suggest that the loss of adherent junction function may be a mechanism by which Merlin 
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deficiency leads to tumor and metastasis development (Bretscher et al., 2002; Lallemand et al., 
2003).  
The tumor suppressor activities of NF2 are closely linked to the critical roles of Merlin in 
contact inhibition of cell growth and proliferation by functioning as an upstream activator of the 
Hippo pathway (Hamaratoglu et al., 2006), in the last two decades Merlin mutations have been 
identified in Neurofibromatosis type 2 and other cancer patients (Rouleau et al., 1993; Bianchi et 
al., 1994; Schroeder et al., 2014). Despite this, the upstream regulators of Merlin in the Hippo 
pathway are poorly understood and there is no current information regarding Merlin involvement 
in prostate cancer. 
One of the other interactions reported between Merlin and Pak2, has been shown in the 
context of Merlin acting as a direct substrate for Pak2. The interaction of Merlin alone with Pak2 
results in the phosphorylation of Merlin at the serine 518 (McClatchey and Giovannini, 2005). 
The phosphorylated form of Merlin has lost its ability to bind Erbin and disrupt Pak2 interaction 
with Rac1 and CDC42. Phosphorylation of Merlin results in its inactivation and degradation 
(Kissil et al., 2003; Wilkes et al., 2009; Xiao et al., 2002), suggesting Pak2 kinase activity is a 
mechanism by which the cell regulates Merlin function. 
1.7 TGF-β interaction with Pak2 Pathway 
The interaction of TGF-β ligand with its receptors TGFβRI and TGFβRII results in the 
activation of the PI3K pathway in a cell type specific manner. In mesenchymal cells TGF-β 
activation of the PI3K pathway, leads either to the activation of the AKT arm of the pathway 
and/or the activation of Pak2 (Wilkes et al., 2003; Wilkes et al., 2005; Moustakas and Heldin, 
2005; Figure 1.5). Although it is not fully understood how downstream of PI3K, the pathway 
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recruits Rac1 and CDC42, Pak2 is activated through the interactions of Rac1 and CDC42. When 
Pak2 is inhibited it is due to interference by the formation of the Merlin and Erbin dimer. This 
dimer disrupts Pak2 interaction with Rac1 and CDC42 (Wilkes et al., 2009). Additionally, Pak2 
is capable of stimulating ERK phosphorylation (Hough et al., 2012) but may also be capable of 
inactivating Merlin by phosphorylating it at Serine 518 (Kissil et al 2002). 
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Figure 1. 5 - TGF-β promotes the activation of the Pak2 pathway 
 Pak2 activation is due to its interaction with Rac1 and CDC42. Merlin and Erbin disrupt Pak2 
interaction with Rac1-CDC42 leading to its inactivation. Pak2 phosphorylates Merlin in the Serine 
516 leading it to its degradation. 
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1.8 Rationale and Hypothesis 
 The effect, consequences or presence of active Pak2 in prostate cancer has not been fully 
elucidated. The steady-state expression levels of the Pak2 pathway proteins in prostate cancer are 
unknown although studies on mRNA levels suggest no change from normal (Siu et al., 2010). 
Previous findings have indicated that Pak2 is involved in the regulation of growth and migration 
of both normal and cancer cells, more specifically, in the promotion of invasion and migration in 
epithelial cancers (Goc et al., 2012; Siu et al., 2010; Somanath and Byzova, 2009; Wilkes et al., 
2003, 2009). Interestingly, TGF-β has been implicated in promoting invasion and migration in 
later stages of prostate cancer, and has also been shown to be secreted by prostate cancers 
(Massagué, 2008; Moustakas and Heldin, 2007). Since prostate adenocarcinoma undergoes EMT 
for the development of metastasis and Pak2 mediates TGF-β stimulation in mesenchymal cells, 
this suggests a potential mechanism for prostate cancer alteration in the response to TGF-β 
(Hough et al., 2012). This thesis will address the expression levels of the Pak2 pathway 
components in prostate cancer cell lines, in order to address the hypothesis: Pak2 activation is 
involved in the aberrant migration of prostate cancer. 
1.9 Objectives 
 Define the protein and gene expression levels within the Pak2 signaling cascade in cell line 
models representing disease progression (inhibitory proteins: Erbin and Merlin, stimulatory 
proteins Rac1 and CDC42), relative to a normal control. 
 Define basal and TGF-β stimulated Pak2 activity levels. 
 Assess the role of TGF-β in mediating Pak2 migratory control. 
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Chapter II – Materials and Methods 
2.1 Cell culture 
Human prostate cancer cells: 22RV-1 (CRL-2505), LNCaP (CRL-1740), PC-3 (CRL-
1435), and DU145 (HTB-81) and human normal prostate epithelial cell RWPE-1 (CRL-11609) 
were obtained from ATTC (American Type Culture Collection; Manassas, VA). Prostate cancer 
cells were grown in their specified growth medium according to ATTC (shown in Table 2.1), 
supplemented with (FBS) fetal bovine serum, as described (PAA Labs Inc.; Etobicoke, ON). For 
drug treatment experiments prostate cancer cells were incubated for 24 hours in their respective 
media, supplemented with 1% FBS, while RWPE-1 cells were incubated in K-SFM media, 
supplemented with 0.05mg/ml of BPE. For the wound healing assay DU145 cells were seeded (8 
× 104) in 24-well plates and grown to confluence for 48 hours. Growth media was supplemented 
with reduced serum (1% FBS) for 24 hours prior to addition of treatments to reduce effects due 
to replication. For other experiments cells were seeded (1 × 105) in 6-well plates and allowed to 
attach for 48 hours. 
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Table 2. 1 - – Prostate cell lines and characteristic 
 
2.2 Western Blotting 
Cells were lysed with (RIPA) Radio-Immunoprecipitation Assay Buffer (Table 2.2) and 
quantified for total protein using a BCA (Bicinchoninic acid) protein assay with a standard curve 
generated using BSA as reference (Pierce/ThermoFisher Scientific; Waltham, MA). Equivalent 
amounts of total protein were separated by polyacrylamide gel electrophoresis and then 
transferred into a polyvinyl difluoride (PVDF) membrane (Immobilon-P; Billerica, MA). 
Primary antibody binding was detected using goat anti-rabbit (Life Technologies/ThermoFisher; 
Carlsbad, CA), goat anti-mouse, goat anti-sheep, HRP conjugate secondary antibody as 
appointed in Table 2.3. (Santa Cruz Biotechnology; Santa Cruz, CA). Specific protein detection 
was visualized with SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher; 
Waltham, MA) and obtaining images of the membranes on the ImageQuant LAS 4000 imager 
and analyzing band densities with ImageQuant TL Software (GE Healthcare Life Sciences; 
Mississauga, ON). Blots were stripped in a solution of 2% SDS, 63mM Tris-HCL (pH 6.8), and 
Cell Name Cells Derived
Biosafety 
Level
Tumorigenic Growth Medium
Added 
Components
Reference
RWPE-1
Epithelial cell line 
derived from the 
peripheral zone
2 No K-SFM
0.05mg/ml PBE 
and 5ng/ml EGF
(Bello D et al., 1997)
22RV-1
Prostate cancer cell 
line derived from a 
Xenograft
2 Yes RPMI-1640 10% FBS (Sramkoski et al., 1999)
LNCaP
Lymph node 
metastasis
1 Yes RPMI-1640 10% FBS
(Horoszewicz et al., 
1983)
PC-3
Bone metastasis of 
grade IV prostate 
adenocarcinoma
1 Yes
F-12K (Kaighn's 
Modification of 
Ham's)
10% FBS (Kaighn et al., 1997)
DU145 Brain metastasis 1 Yes
Eagle's Minimum 
Essential Medium 
(EMEM)
10% FBS (Stone et al., 1978)
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0.1 M β-mercaptoethanol for 10 min at 50 ⁰C. Stripping solution was removed by two washes of 
Tris-buffered saline Tween 20 [(TBST) 50mM Tris, 150mM NaCL, and 0.05% Tween 20] at 
room temperature, followed by blocking and incubation with α-Tubulin antibody to act as 
loading control. 
Table 2. 2 - RIPA Buffer components and concentrations 
 
Stock Solution Volume
10X PBS 0.25 ml
10% Triton-X 0.25 ml
10% Deoxycholic Acid (DOC) 0.125 ml
1M TRIS-HCL pH7.4 0.125 ml
1M β-glycerophosphate 0.125 ml
1M Sodium Fluoride (NaF) 0.125 ml
0.5M Ethylenediaminetetraacetic acid (EDTA) pH7.5 25μl
20% Sodium Deodecyl Suldate (SDS) 12.5μl
10X Protease Inhibitor 0.25 ml
PMSF (Phenylmethylsulfonyl fluoride) (50μg/ml) 7.5μl
Sodium Orthovanidate (200mM) 25μl
Autoclaved dH2O 1.18 ml
Final Volume 2.5 ml
RIPA Buffer
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Table 2. 3 - Western Blot antibodies, source and dilutions 
 
2.3 Drug Treatment 
Human prostate cancer cells were incubated un reduced serum media conditions (1% vs 
10%) in their respective media as described in section 2.1. The cells were treated with 
recombinant human transforming growth factor β1 (TGF-β; Gibco/ThermoFisher; Carlsbad, CA) 
at a concentration of 5ng/ml, EGF (United States Biological/Cedarlane Laboratories; Salem, 
MA) at a concentration of 50ng/ml, Rac1 inhibitor, RacII (EMD Millipore; Etobicoke, ON) at a 
concentration of 50μM, CDC42 inhibitor, ML141 (EMD Millipore; Etobicoke, ON) at a 
concentration of 10μM for the indicated time, and/or  Pak2 inhibitor, Frax1036 (Genentech, CA) 
at a concentration of 1μM for the indicated time. All inhibitors were dissolved in DMSO. Doses 
were obtain following titration of cytotoxic effects determined experimentally by testing cells 
with doses of drug over 2 log orders dilutions. 
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2.4 RNA Extraction and cDNA Synthesis 
Cells were seeded (106 cells/well) in a six-well plate 24 hours prior to treatment. 
Following treatment of Trizol reagent was added to each well (Ambion/ThermoFisher Scientific; 
Carlsbad, CA) for RNA extraction as per manufacture’s instructions. The upper aqueous phase 
was collected and loaded into a Pure Link RNA Mini column (Ambion/Invitrogen; Grand Island, 
NY). Total RNA was isolated according to the manufacturer’s instructions, with RNA integrity 
being assessed with the Agilent RNA 6000 Nano kit on the Bioanalyzer (Agilent Technologies; 
Santa Clara, CA) according to the manufacturer’s instructions. Synthesis of complementary 
DNA (cDNA) was implemented following Applied Biosystems High-Capacity cDNA Reverse 
Transcription kit protocol (Applied Biosystems/ThermoFisher; Foster City, CA). In each 
reaction 1-2 μg of total RNA was used to synthesize cDNA. Samples were diluted with sterile 
H2O to a final concentration of 10ng RNA/cDNA/μl to produce a working stock solution.  
2.5 Quantitative PCR (qPCR) 
qPCR was performed to measure steady state levels of Merlin, Erbin, CDC42, and Rac1 
gene expression in prostate cancer cells and RWPE-1 cells (Table 2.4). A master mix including 
the TaqMan Gene Expression Master Mix 2X (Applied Biosystems/ThermoFisher; Foster City, 
CA), the probe of interest 20X (Applied Biosystems/ThermoFisher; Foster City, CA), 1μl of the 
cDNA (10ng RNA/cDNA), and nuclease-free water to have a final volume of 21μl per reaction. 
Samples were analyzed on ViiA™ 7 Real-Time PCR System (Applied Biosystems/ 
ThermoFisher; Foster City, CA) using the standard 40 cycles run in the system. Data was 
analyzed with the relative quantitative comparison threshold cycle (ΔΔCt) method using 
GAPDH as a control. GAPDH was selected from a group of control probes (18S, HPRT1, and 
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GUSB, and β-actin), based on its consistency between the different cell lines and linearity of 
detection over 3 log order dilutions.  
Table 2. 4 - qPCR TaqMan Probes list 
 
2.6 Wound healing assay for cell migration  
Prostate cancer cells were seeded at various cell number/well (DU145, 8 × 104; PC-3, 1 × 
105; RWPE, 1 × 105) in 24-well plates. Wounds were made using a 200μl pipet tip in confluent 
cells, cultured in 24-well plates. Cells were treated with ML141 (10μM), Frax1036 (1μM), TGF-
β (5μg/ml), and a combination of ML141 or Frax1036 with TGF-β, the cells were allowed to 
migrate into the uncovered area for 12 hours. Doubling time for DU145 is established to be at 34 
hours in the its corresponding complete culture media (Webber et al., 1997), and for PC-3 
doubling time is consider to be approximately 33 hours in its corresponding complete culture 
media (Keer et al., 1990; Rossi and Zetter, 1992). Cell migration was visualized at 10× 
magnification using an inverted Nikon Diaphot microscope (Nikon Instruments Inc.; Melville, 
NY), photographed with a Nikon digital camera D3000 at time 0 and 12h. Plates were marked 
with two lines perpendicular to the wound to ensure correct repeated location of the images. Cell 
free areas were measured as pixel units with the Image J software (National Institute of Health; 
Bethesda, MD). 
GAPDH Hs03929097_g1
CDC42 Hs00918044_g1
RAC1 Hs01025984_m1
NF2 Hs00966302_m1
ERBB2IP Hs01049966_m1
TaqMan® Probes
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2.7 Statistical Analysis  
The difference between experimental groups was analyzed by one-way analysis of 
variants (ANOVA) followed by a Turkey’s post hoc test. P values less than 0.05 were considered 
significant (*P < 0.05; **P < 0.01; ***P < 0.0005; ****P < 0.0001). Statistical analyses were 
performed with Prism 6 software (GraphPad Prism; La Jolla, CA). Each sample for qPCR was 
analyzed in triplicate from a minimum of three RNA replicates isolated from each cell line. 
Samples for western blotting were analyzed from a minimum of five independent protein lysates 
from each cell line. Migration of each cell line was analyzed using a minimum of eight replicates 
of each treatment. 
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Chapter III Results 
3.1 Pak2 protein levels in Prostate Cancer 
In normal mesenchymal cells the interaction of the TGF-β-receptors I and II activates the 
PI3K pathway, which in turn promotes the activation of the Pak2 pathway. Although prostate 
cancer originates from the uncontrolled growth of epithelial cells that do not activate Pak2 in 
response to TGF-β (Wilkes et al., 2003), we believe the EMT process alters the molecular 
signaling pathways to produce mesenchymal signals in epithelial cells. I therefore wanted to first 
examine the steady state levels of proteins within the Pak signaling cascade.  
In order to observe the expression levels of Pak2 protein in prostate cancer, immunoblots 
were performed with a panel of four different prostate cancer cell lines to model different stages 
of prostate cancer progression (Figure 3.1). These levels were compared to a non-malignant 
control RWPE-1. α-Tubulin expression was used as a loading control. The cell lines used were: 
22Rv1 (primary tumor), LNCaP (early androgen responsive tumor), PC-3 and DU145 (androgen 
independent, late tumor), and the normal prostate epithelial cell RWPE (immortalized but non-
tumorigenic). Pak2 protein levels show variation between the prostate cancer cell lines. The 
early tumor cell line LNCaP and the late tumor cell line DU145 show a statistically significance 
difference from the non-malignant control RWPE-1 cell line. However, despite these differences 
there appears to be a significant amount of Pak2 protein in the cell lines with reduced expression. 
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Figure 3. 1 - Pak2 protein expression levels 
Protein expression levels of Pak2 in prostate cancer cell lines corrected for loading control using α-
Tubulin, were determined. Immunoblots (n=5) from five separate cell lysate were performed and 
ANOVA statistical analysis was performed (*P<0.05; **P<0.01). Units shown on the y-axis represent 
pixel density for Pak2 immunoblots derived over the pixel density for α-Tubulin for the same blot. 
3.2 Pak2 stimulatory proteins (Rac1 and CDC42) 
Pak2 activation is due to its interactions with the GTPase proteins Rac1 and CDC42 (Lei 
et al., 2000). In order to determine the levels of the Pak2 stimulatory proteins Rac1 and CDC42, 
immunoblots were performed with an antibody capable of detecting total amount of both 
proteins in the total cell lysates from prostate cancer cell lines 22RV-1, LNCaP, PC-3, and 
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DU145 compared to the non-malignant control RWPE. α-Tubulin antibody was used as a 
loading control. Analysis of the immunoblots showed a significant difference of total amount of 
Rac1 and CDC42 protein levels (Figure 3.2) in all prostate cancer cell lines, especially in the 
later stage tumor cell line DU145, compared to the non-malignant control RWPE.    
                          
Figure 3. 2 - Total protein levels of the Pak2 stimulatory proteins Rac1 and CDC42 
Steady state expression levels of the Pak2 stimulatory proteins Rac1 and CDC42. Immunoblots (n=5) 
were used to identify both proteins, using α-Tubulin as a loading control. Pixel densities from each 
immunoblot were analyzed relative to RWPE (ANOVA and Tukey’s post hoc) to determine 
significance (*P<0.05; **P<0.01; ***P < 0.0005; ****P < 0.0001). 
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3.3 Rac protein and RNA expression levels 
Similar to what was observed when total expression of total Rac1 and CDC42 was 
determined, when we analyzed prostate cancer cell lysate for total Rac (Rac1, 2, 3; Figure 3.3A). 
A significant reduction of total Rac was found in all cell lines, with a trend to lower levels with 
advancement of disease (22RV-1 vs PC-3 – P = 0.058, 22RV-2 vs DU145 – P = 0.0021). 
Of all the Rac isoforms (Rac1, 2, or 3) Rac1 is the most abundant of all three Rac 
proteins (Nobes and Hall, 1995). This data suggests that Rac1 protein levels decrease with 
advancement of the disease. In order to determine if the protein levels are the result of decreased 
gene expression of Rac1, a qPCR was performed on steady state mRNA expression levels of 
Rac1 (Figure 3.3B). Interestingly, Rac1 mRNA levels significantly increased with disease 
progression (LNCaP and PC-3), but Rac1 mRNA levels was not consistent and elevated in 
DU145, where expression was similar to the control RWPE-1. 
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Figure 3. 3 – Total Rac protein levels and gene expression changes in prostate cancer cells 
A- Steady state expression levels of the Pak2 stimulatory protein Rac1. Immunoblots (n=6) were used 
to determine Rac1 levels, using α-Tubulin as a loading control. Pixel densities from each immunoblot 
were analyzed (ANOVA and Tukey’s post hoc) to determine significance (*P<0.05; **P<0.01; ***P < 
0.0005; ****P < 0.0001). B- Steady state of mRNA expression levels of Rac1 was determined by 
qPCR (n=3). Analysis by relative quantitative threshold cycles (ΔΔCT) method was performed, 
results were normalized to a GAPDH internal standard. 
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3.4 CDC42 protein levels and RNA expression levels 
Unlike Rac1, specific antibodies were available to determine the steady state levels of 
CDC42 (Figure 3.4 A). In contrast to what was observed in figures 3.2 and 3.3, relative levels of 
CDC42 increase corresponding to advancement of disease and the acquisition of androgen 
independence (PC-3 and DU145). Although the amount of CDC42 is increasing, the total levels 
of Rac1/CDC42 are significantly decreasing in prostate cancer cell lines compared to the control 
(Figure 3.2). Indicating the ratio of CDC42:Rac1 in these cells is changing dramatically in favor 
of CDC42 over Rac1. 
In contrast to the protein levels, the mRNA levels of CDC42 in DU145 were lower 
(Figure 3.4 B). No significant difference in CDC42 levels were seen in most cancer cell lines 
relative to RWPE-1 control, with PC-3 being the exception with a 3-fold increase in CDC42 
mRNA levels. 
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Figure 3. 4 - Total CDC42 protein levels and gene expression changes in prostate cancer cells 
A- Steady state expression levels of the Pak2 stimulatory protein CDC42. Immunoblots (n=6) were 
used to identify CDC42, using α-Tubulin as a loading control. Pixel densities from each immunoblot 
were analyzed (ANOVA and Tukey’s post hoc) to determine significance (*P<0.05; **P<0.01; ***P < 
0.0005; ****P < 0.0001). B- Steady state of mRNA expression levels of CDC42 was determined by 
qPCR (n=3). Analysis by relative quantitative threshold cycles (ΔΔCT) method was performed, 
results were normalized to a GAPDH internal standard. 
3.5 Expression levels of Pak2 inhibitor Erbin 
Based on the results showing a small decrease in Pak2 protein levels and shift in ratio of 
the Pak2 activator proteins, I decided to examine the levels of the Pak2 inhibitory protein Erbin. 
In order to measure the protein expression levels of Erbin, immunoblots were performed to 
compare total Erbin protein expression levels on prostate cancer cell lines relative to that of 
RWPE control. Using α-Tubulin as a loading control. Analysis of the protein levels demonstrate 
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a significant reduction on Erbin protein levels in all prostate cancer cell lines compare to RWPE. 
qPCR and analysis of mRNA levels were performed to measure Erbin mRNA expression. 
Opposite to what the Erbin protein levels showed (Figure 3.5 A), the change of Erbin gene 
expression in the prostate cancer cell lines LNCaP and DU145 show a significant increase of 3 
and 8-fold respectively (Figure 3.5 B) in comparison to the control RPWE with no difference 
seen in 22RV-1 or PC-3.       
 
Figure 3. 5 - Total protein levels of the Pak2 inhibitory protein Erbin and gene expression levels 
A- Steady state expression levels of the Pak2 inhibitory protein Erbin. Immunoblots (n=6) were used 
to identify Erbin, using α-Tubulin as a loading control. Pixel densities from each immunoblot were 
analyzed (ANOVA and Tukey’s post hoc) to determine significance (*P<0.05; **P<0.01; ****P < 
0.0001). B- Steady state of mRNA expression levels of Erbin was determined by qPCR (n=3). 
Analysis by relative quantitative threshold cycles (ΔΔCT) method was performed, results were 
normalized to a GAPDH internal standard. 
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3.6 Expression of levels of Pak2 inhibitor Merlin 
Based on the observation of previous results showing a shift in the ratio of the Pak2 
activator proteins from Rac1 to CDC42 (Figure 3.3 vs 3.4 in context of figure 3.2), the small 
decrease in Pak2 protein and the decrease in the inhibitory protein Erbin, the levels of Merlin, 
the other Pak2 inhibitory protein, were examined. Total Merlin protein expression was measured 
by immunoblots on prostate cancer cell lines and compared to the control RWPE. Analysis of 
protein data indicate significantly higher Merlin protein levels in all prostate cancer cells 
compared to RWPE (Figure 3.6 A). qPCR for Merlin gene expression levels was assessed using 
GAPDH as an internal standard. The change in Merlin gene expression in the prostate cancer cell 
lines 22RV-1, LNCaP and PC-3 show a significant increase of 2-fold, 7-fold, and 9-fold 
respectively (Figure 3.6 B) in comparison to the control RPWE. 
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Figure 3. 6 - Total protein levels of the Pak2 inhibitory protein Merlin and gene expression levels  
A- Steady state expression levels of the Pak2 inhibitory protein Merlin. Immunoblots (n=6) were 
used to identify Merlin, using α-Tubulin as a loading control. Pixel densities from each immunoblot 
were analyzed (ANOVA and Tukey’s post hoc) to determine significance (*P<0.05; **P<0.01; ****P 
< 0.0001). B- Steady state of mRNA expression levels of Merlin was determined by qPCR (n=3). 
Analysis by relative quantitative threshold cycles (ΔΔCT) method was performed, results were 
normalized to a GAPDH internal standard. 
3.7 Pak2 activity measured by Phospho-Merlin (P-Merlin) levels 
Although Pak2 protein levels showed a small reduction; to observe Pak2 activity, Merlin 
phosphorylation was determined. Pak2 phosphorylates Merlin Serine 518 in order to impair 
Merlin’s function. This phosphorylation directs Merlin to degradation (Kissil et al., 2002). 
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Immunoblots were performed in order to observe steady state Pak2 activity by means of Merlin 
phosphorylation. P-Merlin levels were assessed in the prostate cancer cell lines and compared to 
the non-malignant control RWPE-1 (Figure 3.7 A). The level of Pak2 activity (P-Merlin) as a 
function of the amount of Merlin present showed an increase in Pak2 activity in the advance 
prostate cancer cell lines PC-3 and DU145. However, since Merlin levels changed with disease 
progression (Figure 3.6), we wished to correct for this. Thus by analyzing P-Merlin relative to 
the amount of Merlin present as a function of total cellular protein (corrected for α-Tubulin), it is 
possible to determine relative steady state Pak2 activity. P-Merlin levels were compared against 
total amount of Merlin present and normalised against the loading control α-Tubulin (Figure 3.7 
B). Analysis of the protein data indicated a significant reduction on P-Merlin levels on the 
22RV-1 and LNCaP prostate cancer cell lines compared to RWPE-1 control, and a significant 
increase on P-Merlin levels on the PC-3 and DU145 cells in comparison to the RWPE-1 control, 
suggesting an increase in Pak2 activity. 
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Figure 3. 7 – Pak2 activity measured by P-Merlin expression levels  
A- Steady state expression levels of P-Merlin. Immunoblots (n=6) were used to identify P-Merlin, 
using Merlin as control. B- P-Merlin compared to total Merlin were normalized with α-Tubulin 
loading control. Pixel densities from each immunoblot were analyzed (ANOVA and Tukey’s post 
hoc) to determine significance (*P<0.05; **P<0.01; ***P < 0.0005; ****P < 0.0001).  
3.8 TGF-β effect on GSK-3β activity    
TGF-β interaction with its receptors results in the activation of the PI3K pathway. In 
mesenchymal cells this activation can lead to AKT activation, therefore to the activation of 
GSK-3β (Grimes and Jope, 2001). Immunoblots were performed in order to assess the 
responsiveness of the PI3K pathway to TGF-β stimulation (Guo et al., 2008)  by means of 
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Phospho-GSK-3β (P-GSK-3β) levels against relative amount of total GSK-3β. Treatments with 
TGF-β (5ng/ml) were added to the cells for two different time points (0 hours, 1 hours, and 3 
hours). Levels of P-GSK-3β were corrected using total GSK-3β in order to assess the effect of 
the TGF-β treatment in 22RV-1 and PC-3 cell lines (Figure 3.8). The difference between the 
mean values were obtained from 6 experiments for each cell line at each time point. Analysis of 
the phosphorylation status of GSK-3β indicated no differences on the levels of P-GSK-3β from 
time 0h (unstimulated) in 22RV-1 and PC-3 cell lines with the TGF-β treatment (3h). LNCaP 
cells were not used in this experiment, due to the fact that LNCaP cells do not poses TGF-β 
receptors (Horoszewicz et al., 1983; Kim et al., 1996). Also, RWPE-1 control was not used 
because epithelial cells does not activate the PI3K pathway (Bakin et al., 2000; Wilkes et al., 
2005). These results suggest that TGF-β is not stimulating the activation of AKT pathway as 
shown in figure 1.5. 
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Figure 3. 8 - P-GSK-3β expression levels in the presence of TGF-β 
A- Expression levels of P- GSK-3β in 22RV-1 cells with TGF-β treatment. Immunoblots (n=6) were 
used to identify P-GSK-3β, using total GSK-3β as control. B- Expression levels of P- GSK-3β in PC-3 
cells with TGF-β treatment. Immunoblots (n=6) were used to identify P-GSK-3β, using total GSK-3β 
as control. Pixel densities from each immunoblot were analyzed (ANOVA and Tukey’s post hoc) to 
determine significance (*P<0.05; **P<0.01; ***P < 0.0005; ****P < 0.0001).  
3.9 TGF-β promotes ERK activation through the PI3K pathway  
As observed in previous results TGF-β does not promote the activation of AKT 
(phosphorylation of GSK-3β) in early (22RV-1) and late (PC-3) prostate cancer cell lines. 
However, TGF- β promotes cell growth in mesenchymal cells (Heldin et al., 2009; Principe et 
al., 2014) through ERK phosphorylation via Pak2 in mesenchymal cells, but not epithelial cells 
(Hough et al., 2012; Wilkes et al., 2005).  
 53 
 
Immunoblots were performed in order to review the responsiveness of this arm of the 
PI3K pathway to TGF-β by Phospho-ERK (P-ERK) levels against total amount of ERK (Hough 
et al., 2012). A treatment of 5ng/ml of TGF-β was delivered to the cells for three different time 
points (0 hours, 1 hours, and 3 hours). Levels of P-ERK were corrected for total amount of ERK 
in each cell line (Figure 3.9). Mean values were calculated from 6 experiments for each cell line. 
22RV-1 and DU145 cells show a significant increase of 2-fold in P-ERK levels at 3 hours of 
TGF-β treatment in comparison to the untreated cells. Again, LNCaP cells were not used in this 
experiment, because LNCaP cells do not possess TGF-β receptors (Horoszewicz et al., 1983; 
Kim et al., 1996). PC-3 and RWPE-1 cells showed no response to TGF-β resulting in no 
phosphorylation of ERK (Appendix A1). 
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Figure 3. 9 - P-ERK expression levels in the presence of TGF-β 
A- Expression levels of P- ERK in 22RV-1 cells with TGF-β treatment. Immunoblots (n=6) were used 
to identify P-ERK, using total ERK as control. B- Expression levels of P-ERK in DU145 cells with 
TGF-β treatment. Immunoblots (n=6) were used to identify P-ERK, using total ERK as control. Pixel 
densities from each immunoblot were analyzed (ANOVA and Tukey’s post hoc) to determine 
significance (*P<0.05; ****P < 0.0001).  
3.10 TGF-β effect on Merlin phosphorylation in prostate cell lines 
3.10.1 RWPE-1 Cell Line 
 Previous results show that steady state Merlin phosphorylation levels increased in 
advanced prostate cancer cell lines and that TGF-β promotes ERK phosphorylation, indicating 
the possibility of the ability of TGF-β to promote Pak2 activity in prostate cancer cell lines. 
Merlin has also been reported to act as a direct substrate for Pak2, becoming phosphorylated at 
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the serine 518. This phosphorylation impairs Merlin function and leads Merlin to its degradation 
(Kissil et al., 2002; Wilkes et al., 2009; Xiao et al., 2002).  
 TGF-β influence on Pak2 activity was assessed using P-Merlin levels against the total 
levels of Merlin with immunoblots. Treatment with TGF-β (5ng/ml) was administrated to 
RWPE-1 cells for different time points (0 hours, 1 hours, and 3 hours; Figure 3.10 A). Levels of 
P-Merlin were compared against total amount of Merlin with the TGF-β treatments and 
normalised against the loading control α-Tubulin (Figure 3.10 B). As expected, normal epithelial 
cells do not activate Pak2 as response to TGF-β, RWPE-1 cells showed no response to TGF-β 
treatment, showing no difference in P-Merlin levels compared to total amount of Merlin.  
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Figure 3. 10 - P-Merlin expression levels on normal epithelial cells in the presence of TGF-β 
A- Expression levels of P- Merlin in RWPE-1 cells with TGF-β treatment. Immunoblots (n=6) were 
used to identify P-Merlin, using total Merlin as control. B- P-Merlin compared to total Merlin were 
normalized with α-Tubulin loading control. Pixel densities from each immunoblot were analyzed 
(ANOVA and Tukey’s post hoc) to determine significance (*P<0.05; ****P < 0.0001).  
3.10.2 22RV-1 Cell Line 
The influence of TGF-β on Pak2 activity was assessed using P-Merlin levels against total 
amount of Merlin with immunoblots. TGF-β (5ng/ml) was administrated to 22RV-1 cells for 
different time points (0 hours, 1 hours, and 3 hours; Figure 3.11 A). Levels of P-Merlin were 
compared against total amount of Merlin with the TGF-β treatments and normalised against the 
loading control α-Tubulin (Figure 3.11 B). Analysis of 22RV-1 protein lysate showed a 
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significant increase on P-Merlin levels after 3 hours of TGF-β treatment compared to 
unstimulated cells (Time 0 hours). 
 
Figure 3. 11 - P-Merlin expression levels on 22RV-1 cells in the presence of TGF-β 
A- Expression levels of P- Merlin in 22RV-1 cells with TGF-β treatment. Immunoblots (n=6) were 
used to identify P-Merlin, using total Merlin as control. B- P-Merlin compared to total Merlin were 
normalized with α-Tubulin loading control. Pixel densities from each immunoblot were analyzed 
(ANOVA and Tukey’s post hoc) to determine significance (*P<0.05).  
3.10.3 PC-3 Cell Line 
 The influence of TGF-β on Pak2 activity was determined with P-Merlin levels against 
total amount of Merlin present in immunoblots. Treatment with TGF-β (5ng/ml) was 
administered to PC-3 cell line for different time points (0 hours, 1 hours, and 3 hours; Figure 
3.12 A). Levels of P-Merlin were compared against total amount of Merlin between the TGF-β 
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treatments and normalised against the loading control α-Tubulin (Figure 3.12 B). PC-3 cells 
showed a significant increase on P-Merlin levels in comparison to total amount of Merlin at 3 
hours of TGF-β treatment compared to unstimulated cells (Time 0 hours). 
 
Figure 3. 12 - P-Merlin expression levels on PC-3 cells in the presence of TGF-β  
A- Expression levels of P- Merlin in PC-3 cells with TGF-β treatment. Immunoblots (n=6) were used 
to identify P-Merlin, using total Merlin as control. B- P-Merlin compared to total Merlin were 
normalized with α-Tubulin loading control. Pixel densities from each immunoblot were analyzed 
(ANOVA and Tukey’s post hoc) to determine significance (*P<0.05).  
3.10.4 DU145 Cell Line 
As in the other prostate cancer cell lines the influence of TGF-β on Pak2 activity was 
assessed with P-Merlin levels against total amount of Merlin present in immunoblots. Treatment 
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with TGF-β (5ng/ml) was administered to DU145 cells for different time points (0 hours, 1 
hours, and 3 hours Figure 3.13 A). Levels of P-Merlin were compared against total amount of 
Merlin between the TGF-β treatments and normalised against the loading control α-Tubulin 
(Figure 3.13 B). DU145 cells showed a significant increase on P-Merlin levels in comparison to 
total amount of Merlin at 3 hours of TGF-β treatment compared to unstimulated cells (Time 0 
hours). 
 
Figure 3. 13 - P-Merlin expression levels on DU145 cells in the presence of TGF-β  
A- Expression levels of P- Merlin in DU145 cells with TGF-β treatment. Immunoblots (n=6) were 
used to identify P-Merlin, using total Merlin as control. B- P-Merlin compared to total Merlin were 
normalized with α-Tubulin loading control. Pixel densities from each immunoblot were analyzed 
(ANOVA and Tukey’s post hoc) to determine significance (*P<0.05).  
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3.11 Effect of inhibition of the Pak2 stimulator proteins Rac1 and CDC42 on TGF-β 
response in prostate cell lines 
Although, TGF-β does not stimulate Pak2 phosphorylation of Merlin in normal prostate 
epithelial cells (Figure 3.10), TGF-β and Pak2 each have important functions. As stated in the 
hypothesis (Section 1.8) I am interested in understanding how TGF-β affects prostate cancer 
progression and aggressiveness. As observed in previous results (Figure 3.9), TGF-β can 
aberrantly activate ERK in some prostate cancer cells and not in normal prostate epithelial cells 
(Appendix A1), while TGF-β promotes Merlin phosphorylation in all prostate cancer cell lines 
(Section 3.10), suggesting activation of Pak2. 
3.11.1 RWPE-1 Cell Line 
The effectiveness of inhibitors against the Pak2 activators Rac1 and CDC42 was assessed 
by immunoblots. Pak2 activity was implied by the levels of P-Merlin were compared against 
total amount of Merlin normalised against the loading control α-Tubulin, the effect of Rac1 
inhibitors (RacII) and CDC42 inhibitor (ML141) ±TGF-β (5ng/ml) was measured (Figure 3.14). 
RWPE-1 cells treated with RacII for 6 hours and a combination of RacII with TGF-β, and 
ML141 with TGF-β showed a significant reduction on P-Merlin levels in comparison to total 
amount of Merlin in untreated cells, suggesting in normal cells steady state levels of P-Merlin 
are maintained primarily by Rac1. The unexpected TGF-β + ML141 (inhibition of CDC42) 
decreased P-Merlin ratio is difficult to mechanically explain since other experiment done in the 
laboratory have shown TGF-β inhibits the activation of Pak2 in other normal epithelial cell lines 
and may reflect alterations due to reduce serum conditions. 
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Figure 3. 14 - TGF-β effect on the inhibition of Pak2 stimulatory proteins Rac1 and CDC42 in 
normal epithelial cell RWPE-1 
Expression levels of P-Merlin compared to total Merlin were normalized with α-Tubulin loading 
control in RWPE-1 cells. Immunoblots (n=6) were used to determine P-Merlin levels with ± 
inhibitors (ML141 & RacII) and stimulated with ± TGF-β. Pixel densities from each immunoblot 
were analyzed (ANOVA and Tukey’s post hoc) to determine significance. Letter designations is to 
differentiate between different statistical groups. 
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3.11.2 PC-3 Cell Line 
TGF-β stimulated Pak activation in prostate cell lines (Figure 3.11- 3.13), the 
effectiveness of inhibitors against the Pak2 activators, Rac1 and CDC42, was assessed by 
immunoblots. Stimulation of Pak2 activity was implied by the levels of P-Merlin compared 
against total amount of Merlin normalised to α-Tubulin. The effect of Rac1 inhibitors (RacII) 
and CDC42 inhibitor (ML141) in the presence or absence of TGF-β (5ng/ml) was measured 
(Figure 3.15). PC-3 cells treated with ML141 for 6 hours, with or without TGF-β (3h), showed a 
significant reduction in P-Merlin levels in comparison to untreated cells. As showed previously 
(Figure3.12) PC-3 cells treated with TGF-β for 3 hours showed a significant increase on P-
Merlin levels. Interestingly, although there was no significant effect of the Rac1 inhibitor on P-
Merlin levels relative to untreated cells, the inhibitor was able to eliminate the stimulation effect 
of TGF-β, restoring the P-Merlin levels to those seen with the inhibitor alone. In comparison to 
the control RWPE cell line (Figure 3.14) which I have previously shown the CDC42/Rac1 ratio 
to be different form PC-3 cells (showed more CDC42 than Rac1), this data is consistent with this 
cell-line Pak2 being primarily regulated by CDC42. 
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Figure 3. 15 - TGF-β effect on the inhibition of Pak2 stimulatory proteins Rac1 and CDC42 in PC-3 
Expression levels of P-Merlin compared to total Merlin were normalized with α-Tubulin loading 
control in PC-3 cells. Immunoblots (n=6) were used to determine P-Merlin levels with ± inhibitors 
(ML141 & RacII) and stimulated with ± TGF-β. Pixel densities from each immunoblot were analyzed 
(ANOVA and Tukey’s post hoc) to determine significance. Letter designations is to differentiate 
between different statistical groups. 
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3.11.3 DU145 Cell Line  
With the effectiveness of inhibitors against the Pak2 activators Rac1 and CDC42 
showing an inhibition of TGF-β suggesting Pak2 activity in PC-3 cells, in order to test the 
generalization, I tested another advanced prostate cancer cell, DU145. P-Merlin levels were 
measured and compared against total amount of Merlin normalised to α-Tubulin, the effect of 
Rac1 inhibitors (RacII) and CDC42 inhibitor (ML141) ±TGF-β (5ng/ml) was measured (Figure 
3.16). DU145 cells treated with either ML141 or RacII for 6 hours with or without TGF-β 
showed a significant reduction in P-Merlin levels in comparison to total amount of Merlin in the 
untreated cells. Consistent with previous findings (Figure 3.13), DU145 cells treated with TGF-β 
for 3 hours showed a significant increase on P-Merlin. Although the results for DU145 are 
similar to those of PC-3 in that ML141 dramatically decreased steady state levels of P-Merlin, 
unique to this cell line was that not only did RacII cause a similar decrease, but that both 
inhibitors further reduce P-Merlin levels in the presence of TGF-β. Although the ratio of 
CDC42/Rac1 observed in figures 3.3 vs 3.4 showed a dominance in CDC42, the total amount of 
CDC42/Rac1 in DU145 cells is significantly less than the other prostate cancer cell lines (Figure 
3.2) making both inhibitors effective in reducing Pak2 activity. 
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Figure 3. 16 - TGF-β effect on the inhibition of Pak2 stimulatory proteins Rac1 and CDC42 in DU145 
cells 
Expression levels of P-Merlin compared to total Merlin were normalized with α-Tubulin loading 
control in DU145 cells. Immunoblots (n=6) were used to determine P-Merlin levels with ± inhibitors 
(ML141 & RacII) and stimulated with ± TGF-β. Pixel densities from each immunoblot were analyzed 
(ANOVA and Tukey’s post hoc) to determine significance. Letter designations is to differentiate 
between different statistical groups.  
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3.12 Migration assay in highly metastatic prostate cancer cell lines 
As observed in previous results (Section 3.11), inhibition of the Pak2 stimulatory proteins 
Rac1 and CDC42 (RacII and ML141, respectively), in advanced prostate cancer cell lines 
DU145 and PC-3, stopped the effect generated by TGF-β in promoting Pak2 activation (Merlin 
phosphorylation). Active Pak2 and CDC42 have previously been shown to be involved in the 
promotion of invasion and migration in epithelial cancers such as prostate and ovarian (Goc et 
al., 2012; Siu et al., 2010). Since our observations that steady state Pak2 activity is higher in 
advanced prostate cancer cell lines and that TGF-β increases P-Merlin, suggesting that Pak2 
activity is increased, we wish to determine the role of TGF-β on Pak2 in a functional cell 
migration assay. 
3.12.1 PC-3 Cell Line 
In order to determine the roles of TGF-β and Pak2 in prostate cancer cell migration the 
Pak2 inhibitor (Frax1036) and Pak2 promoter protein CDC42 inhibitor (ML141) were used to 
determine if Pak2 promoted migration in prostate cancer via a wound healing assay. Since 
CDC42 itself is thought to promote cell migration independent of Pak2 (Raftopoulou and Hall, 
2004), the use of both inhibitors allowed us to determine the relative contributions of Pak2 
activity in CDC42 regulated migration. PC-3 cell migration was measured in the presence of 
ML141, Frax1036, with or without TGF-β (5ng/ml) for 12 hours (Figure 3.17). TGF-β treatment 
alone promoted the migration of PC-3 cells, while treatment with Frax1036 or ML141 
significantly reduced migration 20% ± 4. Either of the inhibitors in combination with TGF-β 
reduced the effect of TGF-β alone. 
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Figure 3. 17 - Migration assay in highly metastatic PC-3 cell line 
PC-3 migration with ± inhibitors (ML141 & Frax1036) and stimulated with ± TGF-β (n=8) for 12 
hours. Pixel densities from each cell free area picture were analyzed (ANOVA and Tukey’s post hoc) 
to determine significance. Letter designations is to differentiate between different statistical groups. 
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3.12.2 DU145 Cell Line 
As observed in previous results the effect of Pak2 inhibitors significantly reduced PC-3 
cell migration (Figure 3.17), in order to determine if the Pak2 inhibitor (Frax1036) and Pak2 
promoter protein CDC42 inhibitor (ML141) show similar results to TGF-β and Pak2 promoted 
migration in prostate cancer via a wound healing assay in DU145 was assessed. DU145 cell 
migration was measured in the presence of ML141, Frax1036, with or without TGF-β (5ng/ml) 
for 12 hours (Figure 3.18). TGF-β treatment alone promoted the migration of DU145 cells 
(p<0.05), while treatment with Frax1036 significantly reduced migration by 23% (p<0.0001). 
Either inhibitor in combination with TGF-β removed the stimulated effect generated by TGF-β 
alone (ML141 p<0.0001; Frax1036 p<0.0001). the effect of Frax1036 with or without TGF-β 
suggest much of DU145 cells inherent migration ability is stimulated by its increased basal Pak2 
activity. This data is also consistent with previous data (Figure 3.13), showing an increasing 
effect of TGF-β + ML141 on Pak2 activity (P-Merlin). Although ML141 and TGF-β + ML141 
were not statistically different there was a decrease making TBF-β + ML141 different from no 
treatment. 
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Figure 3. 18 - Migration assay in highly metastatic DU145 cell line 
DU145 migration with ± inhibitors (ML141 & Frax1036) and stimulated with ± TGF-β (n=8) for 12 
hours. Pixel densities from each cell free area picture were analyzed (ANOVA and Tukey’s post hoc) 
to determine significance. Letter designations is to differentiate between different statistical groups 
relative to untreated. 
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3.12.3 RWPE-1 Cell Line 
With the observations of previous experiments (Section 3.12.1 and 3.12.2) inhibitors 
Frax1036 or ML141 having an effect in reducing the migration of advanced prostate cancer cell 
lines PC-3 and DU145, and negating the stimulated effect of TGF-β. The use of the normal 
prostate cell line RWPE-1 as a comparison for the prostate cancer cell lines. RWPE-1 cell 
migration was measured in the presence of ML141, Frac1036, with or without TGF-β (5ng/ml) 
for 12 hours (Figure 3.19). As observed previously (Figure 3.13) TGF-β treatment has no effect 
on the migration of RWPE-1 cells, while the Pak2 inhibitor Frax1036 significantly reduced the 
migration of RWPE-1 cells. The combination of Frax1036 in the presence of TGF-β has the 
same effect as Frax1036 alone. The normal prostate cell line RWPE-1 behaved as a normal 
epithelial cell should, having low inherent migratory capacities, needing Pak2 activity for limited 
migration not stimulated by TGF-β (Rangwala et al., 2005; Wilkes et al., 2009). 
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Figure 3. 19 - Migration assay in normal epithelial cell line RWPE-1 
RWPE migration with ± inhibitors (ML141 & Frax1036) and stimulated with ± TGF-β (n=8) for 12 
hours. Pixel densities from each cell free area picture were analyzed (ANOVA and Tukey’s post hoc) 
to determine significance. Letter designations is to differentiate between different statistical groups. 
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Chapter IV Discussion 
TGF-β is a member of a family of cytokines that control numerous cellular functions 
including cell migration, proliferation, differentiation, apoptosis and EMT (Grant and 
Kyprianou, 2013; Massagué, 2008). Both epithelial and mesenchymal cells possess the TGF-β 
canonical Smad signaling cascade. However, epithelial cells are growth inhibited, while 
mesenchymal cells are growth stimulated by TGF-β, suggesting a difference in the signaling 
mechanism between cell types. 
In normal epithelial cells, TGF-β stops the cell cycle at the G1 stage, induces 
differentiation, or promotes apoptosis. When an epithelial cell is transformed into a cancer cell, 
components of the TGF-β signalling pathway may be mutated (Pasche, 2001), making it 
impossible for TGF-β to negatively control cell replication, leading to its proliferation. To 
exacerbate the problem, the surrounding stromal cells, respond to TGF-β and proliferate further 
promoting an increase in their production of TGF-β. TGF-β acts on the surrounding stromal 
cells, immune cells, endothelial and smooth-muscle to cells, stimulating angiogenesis allowing 
the cancer cells to be more invasive (Heldin et al., 2009; Principe et al., 2014). In my case the 
known normal replication times for our cancer cells were 33 hours for PC-3 cells and 34 hours 
for DU145 (Keer et al., 1990; Rossi and Zetter, 1992) in normal growth medium concentration 
10% FCS (multiple growth factors, maximum stimulation) lead to the conclusion that the results 
observed in the wound healing assays in reduces serum media conditions are due to the 
migration of the cells and not their replication. 
In cancer, TGF-β has a complex role. Initially, it was identified as a tumor suppressor 
since it inhibits the growth of epithelial cells and induces apoptosis (Nguyen and Pollard, 2000). 
However, at later stages of tumor progression TGF-β acts as a tumor promoter (Xie et al., 2002). 
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At a later stage of the disease, the tumor cells lose their ability to be growth arrested by TGF-β 
but retain their ability to undergo EMT, which correlates to increased invasiveness and 
metastasis (Kingsley et al., 2007). My data is consistent with this concept that in advanced 
prostate cancer cells I found that TGF-β not only stimulated an already elevated Pak2 activity 
but this translated to increased mobility of these models of advanced disease. 
 
Pak2 activation by TGF-β is a process that occurs normally in mesenchymal cells, but it 
is not a normal event in epithelial cells. TGF-β induced Pak2 activation is necessary for the 
morphological alterations and proliferative responses induced in mesenchymal cells, such as 
cytoskeletal rearrangement associated with lamellipodia or filopodia and cell migration (Hough 
et al., 2012; Jaffer and Chernoff, 2002; Wilkes et al., 2003). Group A Paks are a major 
downstream effector of the small GTPases Rac1 and CDC42, which are involved in the actin-
based cytoskeletal remodeling. Group A Paks bind to CDC42 and Rac1 through a GTPase 
binding domain (Renkema and Pulkkinen, 2002).  
Rac1, Cdc42 and Pak proteins are important for physiological responses to growth 
factors in normal epithelial cells, such as cell migration, cell adhesion and cytoskeletal 
remodeling (Somanath and Byzova, 2009). These GTPases have been shown to be involved in 
the promotion of invasion and migration in prostate cancer and ovarian cancer cells by regulating 
microtubule dynamics, adhesion and post-mitotic spreading in fibroblasts (Goc et al., 2012; Siu 
et al., 2010). With TGF-β stimulating Pak2 activity in fibroblast and epithelial cancers including 
EMT, we decided to investigate if TGF-β activation of Pak2 may be involved in prostate cancer 
cell migration. 
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4.1 Pak2 protein expression levels in Prostate Cancer 
The Pak family of kinase enzymes are involved in multiple physiological responses in 
normal epithelial cells, but they are also involved in the promotion of invasion and migration in 
cancers such as ovarian and prostate cancer (Goc et al., 2012; Siu et al., 2010; Somanath and 
Byzova, 2009). Pak2 activation results from the interactions of the small GTPases, Rac1 and 
CDC42 with inactive Pak2, through the interactions of TβRI and TβRII receptors with TGF-β, 
PI3K is activated recruiting Rac1 and CDC42 to interact with Pak2. In all cancer cells elevated 
P-Merlin and elevated TGF-β are indicators of Pak2 activation. 
 As an initial step to elucidate the role(s) of Pak signalling in prostate cancer migration, 
we determined protein levels of its pathway components. Pak2 protein expression levels were 
measured in a panel of prostate cancer cells corresponding to the progression of the disease 
(primary tumor: 22RV-1, early Tumor: LNCaP, and late tumor: PC-3 and DU145) and compared 
to a non-malignant control RWPE. The prostate cancer cell lines LNCaP and DU145 had 
similarly lower Pak2 protein levels in comparison to the non-malignant control RWPE. Although 
there are no studies defining Pak2 protein levels in prostate cancer, a recent study has shown 
increased levels of Pak2 phosphorylation, as well as mRNA in castration resistant cancer cells 
(Jiang et al., 2015). There is evidence in ovarian cancer that Pak2 levels remain similar in the 
normal ovarian cells compared to the ovarian cancer cells (Siu et al., 2010). My results (Figures 
3.1, 3.17, and 3.18) together with this data suggests that the reduced levels of Pak2 observed in 
prostate cancer cells lines are biologically relevant. 
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4.2 Expression of Pak2 stimulators Rac1 and CDC42 
The activation of the group A Paks results from the interaction of the Rho GTPase 
proteins Rac1 and CDC42 with the p21-binding domain (PDB), making this Pak family its major 
downstream effector (Jaffer and Chernoff, 2002; Lei et al., 2000). Although Rac1 activation 
promotes prostate cancer motility and migration (Goc et al., 2012), the amount necessary to 
promote cancer motility and migration is unknown. My analysis of the total amount of Rac1 and 
CDC42 show significantly lower levels of both proteins in all prostate cancer cell lines, 
especially in the later stage tumor cell DU145 in comparison to the control RWPE-1. Previous 
studies have reported that Pak2 overexpression or aberrant activation by Rac1 or CDC42 
generates oncogenic effects in cells, including the acquisition of growth signaling autonomy, 
evasion of apoptosis and the promotion of invasion and metastasis (Radu et al., 2014). Since my 
results show that the total amount of Rac1 and CDC42 present in prostate cancer cells is 
significantly less than in normal prostate epithelial cells, the next step was to determine if a 
difference in either was present. Comparatively, Rac protein levels were lower in prostate cancer 
cells compared to RWPE-1, while protein levels of CDC42 increased in the prostate cancer cell 
lines representing the later stages of the disease. My results suggest that the advanced prostate 
cancer cells, PC-3 and DU145, show a dominance of CDC42 over Rac1. Although, both Rac1 
and CDC42 are required for Pak2 activation (Jaffer and Chernoff, 2002; Lei et al., 2000) and 
both of them are considered to be involved in regulating migration and invasion of cancer (Guo 
et al., 2003), it is not clear which one of them is primarily responsible for Pak activation. These 
results indicate that within the metastatic prostate cancer cells the ratio of Rac1 to CDC42 turn in 
favor for CDC42, suggesting a preference in the advance prostate cancer cell lines PC-3 and 
DU145 for the use of CDC42 to induce Pak2 activation and be involved in their migration.  
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The relationship between protein abundance and mRNA expression is not fully 
understood. Protein levels could be different due to changes in the rate of protein synthesis, 
mRNA or degradation. There are reports demonstrating that the regulatory processes controlling 
the steady-state protein abundance change under different cellular conditions (Greenbaum and 
Colangelo, 2003; Vogel and Marcotte, 2012). The following qPCR analysis indicated that 
expression of Rac1 is elevated in the prostate cancer cell lines LNCaP and PC-3, in comparison 
to the control. While the gene expression of CDC42 is elevated only in PC-3. 
4.3 Expression levels of Pak2 inhibitors Erbin and Merlin 
Pak2 activation is due to the interactions of the Rho GTPases Rac1 and CDC42. Pak2 
inhibition has been reported to be achieved by the interaction of Erbin and Merlin complexes 
binding and inactivating GTPase-bound Pak2 in epithelia (Rangwala et al., 2005; Wilkes et al., 
2009). The outcome of interaction of the Erbin/Merlin complex depends upon the cell context. 
For instance, in fibroblasts Pak2 provides growth stimulatory signals and Merlin becomes 
phosphorylated and inactivated likely due to the lower levels of Erbin protein expression 
(McClatchey and Giovannini, 2005; Wilkes et al., 2009). However, in epithelial cells increased 
Pak2 activity results in cell death (Yan et al., 2012). The Erbin/ Merlin complex disrupts Pak2 
interaction with Rac1 and CDC42 resulting in the inactivation of Pak2 (Rangwala et al., 2005; 
Wilkes et al., 2009). My data showed a dramatic reduction in Erbin protein, similar to that seen 
in fibroblasts when compared to epithelial cells (Wilkes et al., 2009). This indicates that the 
prostate cancer cells share more similar expression patterns to fibroblast than epithelial cells with 
respect to Erbin.  
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Merlin protein expression levels measured by immunoblots, showed levels were 
significantly higher in all prostate cancer cells compared to the control. Like Erbin, Merlin gene 
expression levels follow a similar pattern as the protein levels, showing elevated levels in the 
prostate cancer cells 22RV-1, LNCaP, and PC-3 in comparison to the control RWPE-1. As 
previously described, a difference between protein abundance and mRNA expression does not 
necessarily correlate with the protein steady-state levels (Greenbaum and Colangelo, 2003; 
Vogel and Marcotte, 2012). Erbin and Merlin protein expression levels in all prostate cancer cell 
lines display a difference in the ratio similar to that shown previously in fibroblast (Wilkes et al., 
2009), suggesting that the panel of prostate cancer cells are following in a similar protein 
expression profile to mesenchymal and not epithelial cells.  
4.4 Pak2 activity promotes Merlin phosphorylation  
Tumor suppressor Merlin is a protein reported to show two interactions with Pak2. As an 
inhibitor for Pak2 activity, the Merlin/Erbin complex disrupts Pak2 interaction with the GTPases 
Rac1 and CDC42 (Kissil et al., 2003; Rangwala et al., 2005). Merlin also acts as a direct 
substrate for Pak2, becoming phosphorylated at the serine 518. This phosphorylation impairs 
Merlin function and leads Merlin to its degradation (Kissil et al., 2002; Wilkes et al., 2009; Xiao 
et al., 2002).  Merlin localization in the adherent junctions and its interaction with components of 
these junctions suggest the involvement of Merlin in controlling them. The loss or inactivation of 
Merlin may be involved in the development of tumor metastasis (Bretscher et al., 2002; 
Lallemand et al., 2003), since phosphorylation of Merlin by Pak2 inactivates Merlin growth 
suppressive functions (Xiao et al., 2002; Rong et al., 2004). 
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Since Merlin has been shown to be a Pak2 substrate (McClatchey and Giovannini, 2005) 
steady state Pak2 activity levels were implied by measuring P-Merlin levels with immunoblots 
representing a panel of prostate cancer cells (22RV-1, LNCaP, PC-3, and DU145) compared to a 
non-malignant control RWPE-1. The levels of P-Merlin, across the panel of prostate cancer cells 
representing progression of the disease, showed higher levels of P-Merlin at PC-3 and DU145 
cell lines suggesting a higher basal Pak2 activity. These results suggest that Pak2 is more active 
in advanced prostate cancer cells PC-3 and DU145 suggesting its ability to promote the 
malignancy of these cells. My results show that not only did P-Merlin levels increase in 
androgen independent cell lines (advanced disease), but that TGF-β further increased P-Merlin 
levels, suggesting that TGF-β can promote prostate cancer metastasis through its inactivation of 
Merlin. 
4.5 PI3K pathway responsiveness to TGF-β 
TGF-β is an important cytokine that possesses multiple functions, however its activity is 
cell type specific. For instance, in normal epithelial cells, TGF- β stops proliferation and 
promotes apoptosis, while in mesenchymal cells it promotes cell growth through the activation 
of Pak2 via the PI3K pathway (Heldin et al., 2009; Wilkes et al., 2009; Hough et al., 2012; 
Principe et al., 2014). It has been previously reported that TGF-β does not promote the activation 
of the PI3K pathway in epithelial cancers (Wilkes et al., 2003), but the cell activation of the 
PI3K pathway promotes AKT and ERK activation to enhance cancer motility and invasiveness 
(Dumont et al., 2003).  
Our previously discussed data (Merlin/Erbin ratio being similar to fibroblast) and an 
increased basal Pak2 activity (Figure 3.7) all suggests that if EMT alters signalling in these cells, 
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and TGF-β no longer inhibits their growth, it may activate Pak2. In order to evaluate the 
responsiveness of the PI3K pathway to TGF-β, immunoblots were prepared with samples of the 
prostate cancer cells and the control RWPE-1. The samples were treated with TGF-β for 
different periods of time (0 hours, 1 hours, and 3 hours), and checked for P-GSK-3β levels to 
confirm AKT activity and P-ERK levels to imply Pak2 activation as was shown in mesenchymal 
versus epithelial cells (Hough et al., 2012; Wilkes et al., 2005).  
The prostate cancer cells 22RV-1 and PC-3 showed no variation in P-GSK-3β levels 
indicating that TGF-β did not promote activation of the AKT arm of the PI3K pathway. TGF-β 
treatment increased P-ERK levels in 22RV-1 and DU145 prostate cancer cells suggesting the 
activation of Pak2 by TGF-β. Interestingly, as seen in the Appendix A1, treatment with TGF-β 
did not promote ERK phosphorylation in PC-3 prostate cancer cells and non-malignant control 
RWPE-1. In order to confirm if the pathway is functional, treatment with EGF caused 
phosphorylation of ERK indicating that the pathway is functional, and not stimulated by TGF-β 
(Sheikh et al., 2004). PC-3 cells behave in a similar manner to the non-malignant epithelial 
control RWPE-1 in response to ERK phosphorylation stimulated by EGF, indicating that the 
normal response to TGF-β can remain partially intact even in some advanced prostate cancers. 
4.6 TGF-β promotes Pak2 activity in prostate cancer 
The phosphorylation of ERK, in prostate cancer cells, in response to TGF-β suggest that 
TGF-β activates Pak2. Our lab has previously identified ERK as a downstream target of 
activated Pak2 (Hough et al., 2012). In this study, I showed an increase in steady state levels of 
P-Merlin with advanced disease related cell lines (Figure 3.7 B), suggesting steady state Pak2 
activity is increased with disease progression. As a measure of Pak2 activity, I checked for 
 80 
 
differences in Merlin phosphorylation (S518) to indicate Pak2 activity, since this site has 
previously shown to be a target of activated Pak2 (Kissil et al., 2002).  
Since Pak2 is capable of inducing ERK phosphorylation in response to TGF-β, prostate 
cancer cells were treated with TGF-β for different periods of time and P-Merlin levels were 
measured by an immunoblot to provide evidence that TGF-β promoted Pak2 activation. The non-
malignant control RWPE-1 showed no variation of P-Merlin levels with TGF-β treatments, 
consistent with previous reports indicating that TGF-β does not promote Pak2 activity on normal 
epithelial cells (Wilkes et al., 2003; Heldin et al., 2009; Principe et al., 2014). Interestingly, all 
prostate cancer cells were able to respond to TGF-β (22RV-1, PC-3, and DU145) and showed 
increased levels of P-Merlin by 3 hours of TGF-β treatment. These results suggest that TGF-β 
stimulates Pak2 activity at all stages of the disease interpreted by the panel of prostate cancer 
cells showing primary tumor and late tumor cells which means that Pak2 activation by TGF-β 
could enhance the malignancy of the cells.  
4.7 Inhibitors for Rac1 and CDC42 enables TGF-β promoted Pak2 activity  
As previously mentioned, results demonstrated the promotion of Pak2 activity by TGF-β 
treatment in the prostate cancer cells: 22RV-1, PC-3, and DU145 (Figure 3.11 – 3.13). To 
further address the role of Pak2 in transducing the TGF-β signal to Merlin and possibly 
generating the detrimental effect of TGF-β in prostate cancer (Massagué, 2008; Siu et al., 2010), 
P-Merlin levels were measured in the presence of inhibitors of Pak2 promoters, Rac1 (RacII) and 
CDC42 (ML141). The effectiveness of Pak2 inhibition in the presence of exogenous TGF-β was 
tested. The analysis of P-Merlin levels in the non-malignant control RWPE-1 cells suggest that 
TGF-β does not promote Pak2 activity in normal cells, as expected both inhibitors showed a 
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reduction on P-Merlin levels indicating their effectiveness at hindering basal Pak2 activity. In the 
advanced stage prostate cancer cells: PC-3 and DU145, it was confirmed that TGF-β promoted 
Pak2 activity as previously showed (Figure 3.15 - 3.16). For PC-3 cells, Rac1 inhibitor negated 
this effect, and for DU145 cells both inhibitors reduced Pak2 activity and showed to negate the 
effect generated by TGF-β in promoting Pak2 activity. Inhibition of Pak2 with the application of 
CDC42 inhibitor ML141 showed promising results for cancelling the effects generated by TGF-
β in advanced prostate cancer cells PC-3 and DU145. These results indicate that inhibition of the 
Pak2 activator CDC42 can negate the effects generated by TGF-β in advanced prostate cancer 
cells PC-3 and DU145. While there is more to understand and confirm about the cellular effects 
of inhibiting Pak2, this results suggest that the inhibition of Pak2 could be used as therapeutic 
drug to negate the effects generated by TGF-β in prostate cancer. Although there are differences 
in the responses observed in PC-3 and DU145 cells to Rac1 and CDC42 inhibitors, in previous 
results DU145 cells possess much less Rac1 and CDC42 than PC-3 cells (Figure 3.2), with 
DU145 showing a dominance in preference to CDC42, but both cells are driven by Pak2 
activation. 
4.8 Migration assay in highly metastatic prostate cancer cell lines 
TGF-β promotes growth and migration in advanced stages of prostate cancer  (Al-
Azayzih et al., 2015; Massagué, 2008), the mechanism involved in promoting the cancer 
migration is not completely understood. Previous results (Section 3.11) confirm the effectiveness 
of hindering Pak2 activity promoted by TGF-β using an inhibitor for one of Pak2 promotor 
proteins CDC42 (ML141). The next experiments (Section 3.12) assessed the impact of Pak2 
inhibition on the migration of prostate cancer cells. 
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The effect of Pak2 inhibitor Frax1036 and CDC42 inhibitor ML141 was measured in a 
wound healing assay on the highly metastatic prostate cancer cell lines PC-3 and DU145. 
Analysis of the percentage of cell free area demonstrated that Pak2 inhibitor Frax1036 
significantly slowed the migration of DU145 cells in a 12 hours treatment and both inhibitors 
showed the reduced migration effect on PC-3 cells. Treatment with TGF-β resulted in an 
increased migration of PC-3 and DU145 cells. Interestingly as seen in Appendices A2 and A3, 
the combination of ML141 or Frax1036 inhibitors, with TGF-β, resulted in the complete 
suppression of the TGF-β mediated migration.  The inhibition of Pak2 with either CDC42 
inhibitor ML141 or Frax1036 resulted in the reduction of both endogenous migration and 
elimination of TGF-β mediated migration in advanced prostate cancer cells PC-3 and DU145.  
As a control, the migration assay was performed in the prostate normal epithelial cell line 
RWPE-1 (A4), confirming that epithelial cells do not migrate in the presence of Pak2 or with the 
stimulation of TGF-β, also confirming that the effect of the inhibitors (Frax1036 and ML141) 
have no effect on normal prostate epithelial cells compared to the effect they have in prostate 
cancer cells. With the used of inhibitors (ML141 and Frax1036) targeting Pak2, we discovered 
that is possible to stop the promoted migration generated by TGF-β in advanced metastatic 
prostate cancer cells, suggesting that the use of this type of inhibitor could become another tool 
in the treatment for prostate cancer. Although these results only reflect cellular data, the 
replication times for PC-3 cells (33 hours) and DU145 cells (34 hours) in full serum media 
indicate that the observation obtain in the migration assay performed under reduce serum media 
conditions (1% vs 10%) indicate the efficacy of the inhibitors in disrupting cell migration 
generated by Pak2 activity, there is more to understand of their effect in animal models before 
the inhibitors could be used in humans. 
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4.9 Conclusions 
The main purpose of this study was to assess the involvement of Pak2 in regulating 
aberrant prostate cancer cell migration. Results indicated that all prostate cancer cell lines 
studied display a dysregulation of the regulators of Pak2 corresponding with disease progression. 
There is a shift in the ratio of stimulatory proteins, with a dominance of CDC42 corresponding to 
disease progression. The ratio of Merlin to Erbin is altered at all stages of disease. Together this 
indicates a dysregulation of both stimulators and inhibitors that results in an increase in basal 
Pak2 activity, confirmed by the increase in P-Merlin levels corresponding to progression of the 
disease. Additionally, this increased Pak2 activity is further stimulated by TGF-β in all stages of 
the disease, while inhibition of Pak2 prevents both endogenous and TGF-β promoted migration 
of advanced prostate cancer cell lines PC-3 and DU145. In both cases the effect of CDC42 on 
migration could be accounted for Pak2 actions. Additional experiments such as a comparison of 
the effect generated by TGF-β in promoting Pak2 activation in a prostate cancer cells, compared 
the efficacy of ML141 and Frax1036 inhibitors in animal models and in tumor samples would be 
necessary to develop and prove the effectiveness of an inhibitor that could potentially be used in 
the future as treatment for advanced prostate cancer.   
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Appendices 
A 1 - ERK Phosphorylation 
 
Figure A 1 -  ERK phosphorylation in RWPE and PC-3 cells. 
RWPE and PC-3 cells were treated with 100μg/ml of EGF and 5ng/ml of TGF-β to confirm ERK 
phosphorylation. 
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A 2 - DU145 Cell Migration 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2 - DU145 migration in the presence of TGF-β, ML141 and Frax1036  
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A 3 - PC-3 Cell Migration 
 
Figure A 3 – PC-3 migration in the presence of TGF-β, ML141 and Frax1036   
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A 4 - RWPE-1 Cell Migration 
 
 
Figure A 4 – RWPE-1 migration in the presence of TGF-β, ML141 and Frax1036 
  
 
